Wallin C, Bowen S, Roberge C, Richardson L, Brummelte S. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model. Drug Alcohol Depend. 2019;205:107625 pubmed publisher

Lu T, Wang Z, Prativa S, Xu Y, Wang T, Zhang Y, et al. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model. J Neurochem. 2019;148:114-126 pubmed publisher

Hauser A, Chavali S, Masuho I, Jahn L, Martemyanov K, Gloriam D, et al. Pharmacogenomics of GPCR Drug Targets. Cell. 2018;172:41-54.e19 pubmed publisher

Yano T, Yamada M, Inoue D. Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate. Calcif Tissue Int. 2017;101:102-110 pubmed publisher

Nanda S, Brant R, Regier M, Yossuck P. Buprenorphine: a new player in neonatal withdrawal syndrome. W V Med J. 2015;111:16-21 pubmed

Kabadi R, Kouya F, Cohen H, Banik R. Spontaneous pain-like behaviors are more sensitive to morphine and buprenorphine than mechanically evoked behaviors in a rat model of acute postoperative pain. Anesth Analg. 2015;120:472-8 pubmed publisher

Zamani N, Hassanian Moghaddam H, Bayat A, Haghparast A, Shadnia S, Rahimi M, et al. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine. Toxicol Lett. 2015;232:590-4 pubmed publisher

Tsui J, Evans J, Lum P, Hahn J, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174:1974-81 pubmed publisher

Fiellin D, Schottenfeld R, Cutter C, Moore B, Barry D, O Connor P. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:1947-54 pubmed publisher

Remy A, Wenger H, Bouchkira H. [Treatment of chronic hepatitis C in drug users: ethic, successful and useful]. Presse Med. 2014;43:1314-6 pubmed publisher

Newman R. Risk reduction with buprenorphine-naloxone and methadone: patient's choice. J Acquir Immune Defic Syndr. 2014;67:e142 pubmed publisher

Li X, Shorter D, Kosten T. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. Expert Opin Pharmacother. 2014;15:2263-75 pubmed publisher

Brogly S, Saia K, Walley A, Du H, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180:673-86 pubmed publisher

Clark R, Baxter J, Barton B, Aweh G, O Connell E, Fisher W. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49:1964-79 pubmed publisher

Healy J, Tonkin J, Kamarec S, Saludes M, Ibrahim S, Matsumoto R, et al. Evaluation of an improved sustained-release buprenorphine formulation for use in mice. Am J Vet Res. 2014;75:619-25 pubmed publisher

Sjöberg C. [It is both permitted and forbidden to drive after taking drugs]. Lakartidningen. 2014;111:810-1 pubmed

Patrick M, Dunn K, Badger G, Heil S, Higgins S, Sigmon S. Spontaneous reductions in smoking during double-blind buprenorphine detoxification. Addict Behav. 2014;39:1353-6 pubmed publisher

Cohier C, Chevillard L, Risède P, Roussel O, Megarbane B. Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats. Toxicol Lett. 2014;228:75-84 pubmed publisher

Zhu A, Zhou Q, Cox L, David S, Ahluwalia J, Benowitz N, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin Pharmacol Ther. 2014;96:256-65 pubmed publisher

Olsen Y, Sharfstein J. Confronting the stigma of opioid use disorder--and its treatment. JAMA. 2014;311:1393-4 pubmed publisher

Chakravorty A, Awad M, Hiscox T, Cheung J, Choo J, Lyras D, et al. Opioid analgesics stop the development of clostridial gas gangrene. J Infect Dis. 2014;210:483-92 pubmed publisher

Chen K, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120:1262-74 pubmed publisher

Sigmon S. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71:359-60 pubmed publisher

Heilig M. [Opioid dependence: New national guidelines must allow maintenance treatment]. Lakartidningen. 2013;110:1908-9 pubmed

Uehara M, Inaoka M, Miyaki Y, Nakashima S, Fuzii A, Higami T. [Neuroleptic malignant syndrome after cardiac surgery]. Kyobu Geka. 2013;66:1052-5 pubmed

Wu C, Hung C, Shen C, Chen W, Chang C, Pan H, et al. Prenatal buprenorphine exposure decreases neurogenesis in rats. Toxicol Lett. 2014;225:92-101 pubmed publisher

Tompkins D, Smith M, Mintzer M, Campbell C, Strain E. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2014;348:217-26 pubmed publisher

Salama Hanna J, Chen G. Patients with chronic pain. Med Clin North Am. 2013;97:1201-15 pubmed publisher

Sigmon S, Dunn K, Saulsgiver K, Patrick M, Badger G, Heil S, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry. 2013;70:1347-54 pubmed publisher

. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther. 2013;55:83 pubmed

Edwards R, McCormick Deaton C, Hosanagar A. Acute urinary retention secondary to buprenorphine administration. Am J Emerg Med. 2014;32:109.e1-2 pubmed publisher

Jones H, Deppen K, Hudak M, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210:302-310 pubmed publisher

Jungen H, Andresen Streichert H, Muller A, Iwersen Bergmann S. Disaccharides in urine samples as markers of intravenous abuse of methadone and buprenorphine. J Anal Toxicol. 2013;37:652-8 pubmed publisher

Guo A, Ma J, Best B, Atayee R. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine. J Anal Toxicol. 2013;37:636-41 pubmed publisher

Lavonas E, Banner W, Bradt P, Bucher Bartelson B, Brown K, Rajan P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr. 2013;163:1377-83.e1-3 pubmed publisher

Clement P, Beuselinck B, Mertens P, Cornelissen P, Menten J. Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine. Acta Clin Belg. 2013;68:87-91 pubmed

Bouab O, Lahmek P, Meunier N, Aubin H, Michel L. [Maintaining opioid abstinence long after inpatient treatment with opioid substitution in an addictology hospital unit]. Rev Med Brux. 2013;34:132-40 pubmed

Seppala M. A comprehensive response to the opioid epidemic: Hazelden's approach. Minn Med. 2013;96:45-7 pubmed

Leppert W, Kowalski G. Methadone as an additional opioid for a cancer patient with severe neuropathic and bone pain not responsive to other opioids and adjuvant analgesics. J Palliat Care. 2013;29:119-21 pubmed

Naing C, Aung K, Racloz V, Yeoh P. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol. 2013;139:1963-70 pubmed publisher

Dupouy J, Bez J, Barsony J, Oustric S, Lapeyre Mestre M. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice]. Therapie. 2013;68:155-61 pubmed publisher

Clark R, Baxter J. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?. JAMA Intern Med. 2013;173:1571-2 pubmed publisher

Comer S, Metz V, Cooper Z, Kowalczyk W, Jones J, Sullivan M, et al. Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behav Pharmacol. 2013;24:504-16 pubmed publisher

Wilcox C, Bogenschutz M, Nakazawa M, Woody G. Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants. Addict Behav. 2013;38:2568-74 pubmed publisher

Ray R, Vaswani M, Deb K, Sethi H, Chopra A, Kishore N, et al. Post marketing surveillance of sublingual buprenorphine naloxone combination tablets. Indian J Physiol Pharmacol. 2012;56:359-66 pubmed

Sherman S, Han J, Welsh C, Chaulk P, Serio Chapman C. Efforts to reduce overdose deaths. Am J Public Health. 2013;103:e1-2 pubmed publisher

Schwartz R, Gryczynski J, O Grady K, Sharfstein J, Warren G, Olsen Y, et al. Schwartz et al. respond. Am J Public Health. 2013;103:e2-3 pubmed publisher

Menten J, Carpentier I, Deschutter H, Nuyts S, Van Beek K. The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients. Cancer Invest. 2013;31:412-20 pubmed publisher

Love E, Taylor P, Whay H, Murrell J. Postcastration analgesia in ponies using buprenorphine hydrochloride. Vet Rec. 2013;172:635 pubmed publisher

Sohler N, Weiss L, Egan J, Lopez C, Favaro J, CORDERO R, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013;9:111-9 pubmed publisher

Chawla J, Pal H, Lal R, Jain R, Schooler N, Balhara Y. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects. J Opioid Manag. 2013;9:35-41 pubmed publisher

Ledoux Y. Basic epidemiology of opiate misuse substitution treatment in Belgium. J Pharm Belg. 2012;:30-9 pubmed

Wahle K, Krings D, Schwenke K. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study]. MMW Fortschr Med. 2013;155 Suppl 1:25-31 pubmed

Sukhtankar D, Zaveri N, Husbands S, Ko M. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/?-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther. 2013;346:11-22 pubmed publisher

Webster P. Indigenous Canadians confront prescription opioid misuse. Lancet. 2013;381:1447-8 pubmed

Cropsey K, Lane P, Perkins A, Clark C, Hardy S, McCullumsmith C, et al. Buprenorphine and medication management in a community corrections population: a pilot study. J Addict Med. 2013;7:210-5 pubmed publisher

Bruce R, Winkle P, Custodio J, Wei L, Rhee M, Kearney B, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acquir Immune Defic Syndr. 2013;63:480-4 pubmed publisher

Gryczynski J, Mitchell S, Jaffe J, Kelly S, Myers C, O Grady K, et al. Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat. 2013;45:287-92 pubmed publisher

Israel J, Poore S. The clinical conundrum of perioperative pain management in patients with opioid dependence: lessons from two cases. Plast Reconstr Surg. 2013;131:657e-8e pubmed publisher

Macintyre P, Russell R, Usher K, Gaughwin M, Huxtable C. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013;41:222-30 pubmed

Laprévote V, Geoffroy P, Rolland B, Leheup B, Di Patrizio P, Cottencin O, et al. [Management of opioid maintenance treatments when analgesic treatments are required]. Presse Med. 2013;42:1085-90 pubmed publisher

Collin C, Tricotel A, Courné M. [About the opioid substitution treatment]. Rev Epidemiol Sante Publique. 2013;61:93-4 pubmed publisher

Lin H, Chen C, Huang C, Chen S, Lua A. Simultaneous determination of opiates, methadone, buprenorphine and metabolites in human urine by superficially porous liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;925:10-5 pubmed publisher

Rolland B, Muyssen A, Danel T, Cottencin O. [Should high-dose buprenorphine be withdrawn from the French market?]. Rev Epidemiol Sante Publique. 2013;61:91-2 pubmed publisher

Schwartz R, Gryczynski J, O Grady K, Sharfstein J, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103:917-22 pubmed publisher

Rahimi Movaghar A, Amin Esmaeili M, Hefazi M, Yousefi Nooraie R. Pharmacological therapies for maintenance treatments of opium dependence. Cochrane Database Syst Rev. 2013;:CD007775 pubmed publisher

Berg T, Jørgenrud B, Strand D. Determination of buprenorphine, fentanyl and LSD in whole blood by UPLC-MS-MS. J Anal Toxicol. 2013;37:159-65 pubmed publisher

Alexander T, Iglesia E, Park Y, Duncan D, Peden D, Sheikh S, et al. Severe DRESS syndrome managed with therapeutic plasma exchange. Pediatrics. 2013;131:e945-9 pubmed publisher

Alves M, Piccinotti A, Tameni S, Polettini A. Evaluation of buprenorphine LUCIO immunoassay versus GC-MS using urines from a workplace drug testing program. J Anal Toxicol. 2013;37:175-8 pubmed publisher

Tetrault J, Kozal M, Chiarella J, Sullivan L, Dinh A, Fiellin D. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med. 2013;7:102-7 pubmed publisher

Ho T, Kuo C, Wang S, Chen G, Tseng Y. True ion pick (TIPick): a denoising and peak picking algorithm to extract ion signals from liquid chromatography/mass spectrometry data. J Mass Spectrom. 2013;48:234-42 pubmed publisher

Alhaddad H, Cisternino S, Saubamea B, Schlatter J, Chiadmi F, Risède P, et al. Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice. Toxicology. 2013;305:99-108 pubmed publisher

Miller K, Yarlas A, Wen W, Dain B, Lynch S, Brennan M, et al. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother. 2013;14:269-77 pubmed publisher

Becerra L, Upadhyay J, Chang P, Bishop J, Anderson J, Baumgartner R, et al. Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J Pharmacol Exp Ther. 2013;345:41-51 pubmed publisher

Yang Y, Gao Y, Mei X. Effects of formulation parameters on encapsulation efficiency and release behavior of thienorphine loaded PLGA microspheres. Pharm Dev Technol. 2013;18:1169-74 pubmed publisher

Lee H, Youn J, Gallagher M, Holland P. Temporally limited role of substantia nigra-central amygdala connections in surprise-induced enhancement of learning. Eur J Neurosci. 2008;27:3043-9 pubmed publisher